Sosei Heptares wins early $2.5m payout from Novartis
Sosei Heptares, which has its chief R & D operations in Cambridge UK, has secured a $2.5 million milestone payment from a partnership with Novartis after a potential new inhaled combination therapy for asthma was filed with the European Medicines Agency earlier than expected.
The filing of the therapy, QVM149 was previously planned for Q4 2019.
QVM149 is an investigational, once-daily, fixed dose combination asthma treatment. One of the core ingredients plus certain intellectual property relating to its use and formulation were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura Group, which also has an R & D hub in Cambridge.
Novartis is responsible for the development and commercialisation of QVM149 which is currently being investigated in Phase III/IIIb studies expected to complete in Q3 2019.
Shinichi Tamura, chairman, president and CEO of Sosei Heptares, said: “The acceptance of the MAA submission for QVM149 is an important milestone in the development of this novel, once daily, inhaled combination therapy for asthma patients.
“More than one-third of asthma patients have uncontrolled disease despite the availability of multiple therapies. With the filing of the MAA for approval in Europe we are greatly looking forward to see QVM149 become available to patients and improve the lives of those with uncontrolled asthma.”
Sosei Heptares is headquartered in Japan, listed on the Tokyo stock exchange and has its main R & D nerve centre in Cambridge’s technology hotspot.